An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01667432 |
Recruitment Status
:
Completed
First Posted
: August 17, 2012
Results First Posted
: December 7, 2015
Last Update Posted
: April 10, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Hepatitis B, Chronic | Biological: Peginterferon alfa-2a |
Study Type : | Observational |
Actual Enrollment : | 141 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Multicenter, Prospective, Observational, Non-interventional Study Evaluating On-treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD) |
Actual Study Start Date : | July 8, 2011 |
Actual Primary Completion Date : | August 12, 2014 |
Actual Study Completion Date : | August 12, 2014 |

Group/Cohort | Intervention/treatment |
---|---|
Peginterferon alfa-2a
Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
|
Biological: Peginterferon alfa-2a
Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
Other Names:
|
- Percentage of Participants With Suppression of HBV DNA to < 2,000 IU/ml at the End of the Study [ Time Frame: At the end of the study (Week 36) ]Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) was assessed in plasma samples using quantitative polymerase chain reaction (PCR). Results are reported in international units (IU) per milliliter (ml).
- Percentage of Patients With Suppression of HBV DNA < 2,000 IU/ml [ Time Frame: approximately 3 years ]
- In HBeAg Positive Patients: Percentage of Patients Who Become HBeAg Negative and Anti-HBe Positive [ Time Frame: approximately 3 years ]
- Percentage of Participants With Suppression of HBV DNA to < 80 IU/ml at the End of Treatment [ Time Frame: At the end of treatment (Week 24) ]Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) was assessed in plasma samples using quantitative polymerase chain reaction (PCR). Results are reported in international units (IU) per milliliter (ml) separately for participants who were hepatitis B envelope antigen (HBeAg) positive and HBeAg negative.
- HBsAg Clearance: Percentage of Patients Who Become HBsAg Negative [ Time Frame: approximately 3 years ]
- Correlation of HBsAg Clearance With Other On-treatment Factors in HBeAg Positive and HBeAg Negative Patients [ Time Frame: approximately 3 years ]
- Correlation of HBsAg Clearance With Pre-treatment Factors in HBeAg Positive and HBeAg Negative Patients [ Time Frame: approximately 3 years ]
- Incidence of Serum ALT Normalization: Serum ALT/ALT Ratio [ Time Frame: approximately 3 years ]
- Safety: Incidence of Adverse Events [ Time Frame: approximately 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Adult patients ≥ 18 years of age.
- Hepatitis B envelope antigen (HBeAg) positive or HBeAg negative hepatitis B with or without cirrhosis.
- Elevated alanine aminotransferase (ALT) > upper limit of normal (ULN) but ≤ 10 x ULN according to local label.
Exclusion Criteria:
- Contraindications to peginterferon alfa-2a (PEGASYS®) as detailed in the label.
- Co-infection with hepatitis A, hepatitis C, or human immunodeficiency virus (HIV).
- Concomitant treatment with telbivudine.
- Pregnant or lactating women.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01667432
Bulgaria | |
Mhat - Pleven; Clinic of Gastroenterology | |
Pleven, Bulgaria, 5800 | |
Umhat St. Georgi; Clinical of Gastroenterology | |
Plovdiv, Bulgaria, 4002 | |
MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases | |
Sofia, Bulgaria, 1407 | |
UMHAT Alexandrovska EAD; Gastroenterology | |
Sofia, Bulgaria, 1431 | |
Mhat Queenjoanna; Clinic of Gastroenterology | |
Sofia, Bulgaria, 1527 | |
Military Medical Academy; Gastroenterology | |
Sofia, Bulgaria, 1606 | |
Mhat St. Ivan Rilski; Clinic of Gastroenterology | |
Sofia, Bulgaria, 1612 | |
Mhat St. Zagora; Clinical of Gastroenterology | |
Stara Zagora, Bulgaria, 6000 | |
Mhat Sveta Marina; Clinic of Gastroenterology | |
Varna, Bulgaria, 9010 |
Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT01667432 History of Changes |
Other Study ID Numbers: |
ML25626 |
First Posted: | August 17, 2012 Key Record Dates |
Results First Posted: | December 7, 2015 |
Last Update Posted: | April 10, 2017 |
Last Verified: | March 2017 |
Additional relevant MeSH terms:
Hepatitis Hepatitis A Hepatitis, Chronic Hepatitis B Hepatitis B, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections |
Picornaviridae Infections RNA Virus Infections Hepadnaviridae Infections DNA Virus Infections Peginterferon alfa-2a Interferon-alpha Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs |